Evelo Biosciences Inc
Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriasis . The company is also developing EDP1867, a non-live pharmaceutical preparation fo… Read more
Evelo Biosciences Inc (EVLO) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2023: 0.390x
Based on the latest financial reports, Evelo Biosciences Inc (EVLO) has a cash flow conversion efficiency ratio of 0.390x as of September 2023.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-10.41 Million) by net assets ($-26.71 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Evelo Biosciences Inc - Cash Flow Conversion Efficiency Trend (2016–2022)
This chart illustrates how Evelo Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Evelo Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Evelo Biosciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
IMPIANTI S.P.A.
F:F67
|
N/A |
|
Staige One AG
XETRA:SPC
|
N/A |
|
BSLI3F
SA:BSLI3F
|
N/A |
|
Igiant Optics Co., Ltd.
TWO:6915
|
N/A |
|
Traccom Inc
PINK:TRCC
|
N/A |
|
METALS X (FG5.SG)
STU:FG5
|
N/A |
|
CHINA UNICOM (HK) - Dusseldorf Stock Exchang
DU:XCI
|
N/A |
|
BMGB4F
SA:BMGB4F
|
N/A |
Annual Cash Flow Conversion Efficiency for Evelo Biosciences Inc (2016–2022)
The table below shows the annual cash flow conversion efficiency of Evelo Biosciences Inc from 2016 to 2022.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2022-12-31 | $-4.99 Million | $-101.23 Million | 20.279x | +281.71% |
| 2021-12-31 | $8.67 Million | $-96.72 Million | -11.160x | -365.65% |
| 2020-12-31 | $30.48 Million | $-73.06 Million | -2.397x | -100.44% |
| 2019-12-31 | $60.20 Million | $-71.98 Million | -1.196x | -246.36% |
| 2018-12-31 | $136.95 Million | $-47.28 Million | -0.345x | +56.37% |
| 2017-12-31 | $29.40 Million | $-23.27 Million | -0.791x | +64.49% |
| 2016-12-31 | $5.53 Million | $-12.31 Million | -2.228x | -- |